ProHealth fibromyalgia Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|

Trending News

10 "Healthy" Foods That Are NOT Fibro-Friendly

VIDEO: What It Feels Like To Live With Fibro

Fibromyalgia Research Update from Integrated Tissue Dynamics

SURVEY: Patient Experience with Physicians

VIDEO: Treating Fibromyalgia with Oxytocin

The Brain Boosting and Fatigue Fighting B-12

Fibromyalgia, Family and Friends: 8 Ways to Improve Relationships

Sweet Tips for Fibromyalgia Success

Fibromyalgia and Disability Claims

Melatonin Regulates Inflammation Resolution in Fibromyalgia and Other Disorders

 
Print Page
Email Article

Transcript of FDA’s Sep 13 ME/CFS Stakeholder Teleconference

  [ 6 votes ]   [ Discuss This Article ]
www.ProHealth.com • September 19, 2012


On September 13, a group of 50 FDA officials, pharmaceutical developers, and ME/CFS patients & advocates met via a 90-minute telephone conference. It was a big step in the FDA’s plan for hastening development, testing and approval of drugs to treat ME/CFS - a serious disease with 'unmet medical need'.(1)

The FDA.gov page dedicated to sharing information about these activities has now posted the transcript of this discussion (www.fda.gov/downloads/Drugs/NewsEvents/UCM320310.pdf). It includes input from many stakeholders, and is well worth reading.

The meeting was led by Dr. Sandra Kweder, MD, deputy director of the FDA/CDER’s Office of New Drugs. Just a few of the key points she covered in this very interesting meeting are as follows:

• Importantly, Dr. Kweder established that the FDA considers ME/CFS to be in the category of “serious or life threatening diseases.” And that the FDA is committed to making promising drugs available to individuals with such diseases for which there are as yet no approved drugs as quickly as possible via “the rapid development and review of these types of therapy” - a process called ‘the accelerated approval process.’

• Second, Dr. Kweder emphasized it is very important to identify factors that if measured can be considered trial outcome measures. Using HIV just as an example, she noted, what really revolutionized the study of drugs for HIV/AIDS treatment “was finding something to measure in the clinical trials. In that case they had the… fortune or misfortune to be able to identify some marker in the blood that was predictive of the clinical course of the disease. In the beginning it was a type of white blood cell, CDR lymphocytes.”

• As the drug developers further explained, they have learned from experience, “you’ve got to be able to define the condition well… and know where are the rules about studying it. What am I going to have to show in order to get a drug approved.”

• So, respecting the need for measures and rules, said Dr. Kweder, “We are planning to hold a scientific workshop that explores how to identify valid, reliable, quantitative outcome measures to determine if disease symptoms do improve with specific interventions.”

• The workshop, which CDER (Center for Drug Evaluation and Research) plans to host in spring, 2013, will be open to the public and will “explore a multitude of scientific issues about identifying valid, reliable and measurable outcomes to determine if disease symptoms improve with intervention.” As part of this discussion, says Dr. Kweder, “we want to hear from academic experts, from clinical practitioners who are taking care of patients with these conditions, and patients themselves.”

• In the meantime, the FDA will describe the drug review process in detail for the benefit of all viewing the CFSAC meeting in Washington Oct 3 & 4.

• And in mid-November (date to be determined) the FDA will host an Excellence in Advocacy webinar that will “advise patient advocates or advocacy groups on how to come together and develop common themes to… further your mutual goals” with regard to the process of getting drug therapies for ME/CFS approved.

____

1. See a brief report circulated after the Sep 13 telephone conference by Rivka, a patient activist who participated in the meeting. “FDA Pronounces ME/CFS ‘Serious and Life Threatening Disease in Sep 13 Meet.”




Discuss This Article Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Fibro Freedom™ Fibro Freedom™
Soothes, strengthens & revitalizes
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health

Natural Remedies

Sweet Tips for Fibromyalgia Success Sweet Tips for Fibromyalgia Success
Protect Against Sun-Induced Skin Aging From The Inside Out Protect Against Sun-Induced Skin Aging From The Inside Out
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss
The Curcumin Revolution: The Curcumin Revolution: "Golden" Ticket to Better Health

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing